- Home
- KIO vs CRVS Comparison
KIO vs CRVS Comparison
Compare KIO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- CRVS
- Stock Information
- Founded
- KIO 2011
- CRVS 2014
- Country
- KIO United States
- CRVS United States
- Employees
- KIO 2400
- CRVS N/A
- Industry
- KIO Investment Managers
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- KIO Finance
- CRVS Health Care
- Exchange
- KIO Nasdaq
- CRVS Nasdaq
- Market Cap
- KIO 404.1M
- CRVS 451.0M
- IPO Year
- KIO N/A
- CRVS 2016
- Fundamental
- Price
- KIO $13.73
- CRVS $8.95
- Analyst Decision
- KIO
- CRVS Buy
- Analyst Count
- KIO 0
- CRVS 4
- Target Price
- KIO N/A
- CRVS $10.83
- AVG Volume (30 Days)
- KIO 136.5K
- CRVS 1.0M
- Earning Date
- KIO 01-01-0001
- CRVS 11-12-2024
- Dividend Yield
- KIO 10.82%
- CRVS N/A
- EPS Growth
- KIO N/A
- CRVS N/A
- EPS
- KIO N/A
- CRVS N/A
- Revenue
- KIO N/A
- CRVS N/A
- Revenue This Year
- KIO N/A
- CRVS N/A
- Revenue Next Year
- KIO N/A
- CRVS N/A
- P/E Ratio
- KIO N/A
- CRVS N/A
- Revenue Growth
- KIO N/A
- CRVS N/A
- 52 Week Low
- KIO $10.52
- CRVS $1.23
- 52 Week High
- KIO $13.59
- CRVS $9.70
- Technical
- Relative Strength Index (RSI)
- KIO 31.49
- CRVS 70.45
- Support Level
- KIO $13.63
- CRVS $7.91
- Resistance Level
- KIO $14.06
- CRVS $9.70
- Average True Range (ATR)
- KIO 0.15
- CRVS 0.75
- MACD
- KIO -0.03
- CRVS -0.01
- Stochastic Oscillator
- KIO 23.48
- CRVS 67.51
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).